OAM
RPRX

Oxford Asset Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Oxford Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-51,359
Closed -$68K – 1591
2016
Q4 		$68K Buy
+51,359
New +$89.3K ﹤0.01% 741
2015
Q4 		– Sell
-122,264
Closed -$908K – 1075
2015
Q3 		$908K Buy
+122,264
New +$935K 0.03% 419
2013
Q4 		– Sell
-21,480
Closed -$576K – 957
2013
Q3 		$576K Buy
+21,480
New +$460K 0.01% 645

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Oxford Asset Management's RPRX Position: Q1 2017 in Review

Oxford Asset Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2017, closing a stake of 51,359 shares — an estimated $68K sold.

Oxford Asset Management first reported a position in RPRX in Q3 2013 and held it in 3 quarters. The position peaked at $908K in Q3 2015. 33 funds tracked by Wall St. Rank hold RPRX as of Q1 2017.

  • Oxford Asset Management reported no remaining Repros Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
  • Oxford Asset Management sold 51,359 Repros Therapeutics Inc. shares in Q1 2017, an estimated $68K.
  • Oxford Asset Management first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 3 quarters.
  • Oxford Asset Management's Repros Therapeutics Inc. position peaked at $908K in Q3 2015.
  • 33 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2017.

Based on Oxford Asset Management's 13F filing for Q1 2017, filed 9 May 2017.